Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
01-03 April, 2025
Peptide-Based Therapeu...Peptide-Based Therapeutics Summit
Not Confirmed
Not Confirmed
01-03 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
01-03 April, 2025
Peptide-Based Therapeu...Peptide-Based Therapeutics Summit
Industry Trade Show
Not Confirmed
01-03 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
30 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/harmony-biosciences-acquires-epygenix-therapeutics-inc-adding-late-stage-epilepsy-franchise-to-growing-pipeline-of-innovative-cns-assets-302131000.html
21 Jul 2022
// PHARMIWEB
https://www.pharmiweb.com/press-release/2022-07-21/epygenix-therapeutics-to-participate-in-rw-bairds-biotech-discovery-series
15 Mar 2022
// CONTRACTPHARMA
https://www.contractpharma.com/contents/view_breaking-news/2022-03-15/epygenix-therapeutics-names-darren-cline-as-president-and-ceo/?widget=listSection
30 Aug 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-fda-acceptance-of-ind-to-initiate-a-clinical-trial-of-epx-100-to-treat-lennox-gastaut-syndrome-301364855.html
02 Aug 2021
// PHARMABIZ
12 Nov 2020
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html
ABOUT THIS PAGE